Back to top

immuno-therapy: Archive

Zacks Equity Research

CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss

CRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well.

VRTXPositive Net Change UTHRNegative Net Change LGNDPositive Net Change CRSPNegative Net Change

Zacks Equity Research

Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?

Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.

REGNPositive Net Change PFENegative Net Change NVOPositive Net Change AMGNNegative Net Change MRNANegative Net Change

Zacks Equity Research

Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why

Enlivex (ENLV) plunges after it shares mixed results from a mid-stage study evaluating its lead drug as a potential treatment for sepsis.

LGNDPositive Net Change ANIPPositive Net Change ADMAPositive Net Change ENLVNegative Net Change